Close
Latest news from the CENTAUR trial puts AMX0035 in the mix

Latest news from the CENTAUR trial puts AMX0035 in the mix

Reading Time: 2 minutes This week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried out across multiple North American clinics. The paper was published in the New England Journal of Medicine. The centaur of Greek mythology was a mix of man and horse, so…

Targeting Tregs: IMODALS study paves the way for MIROCALS

Targeting Tregs: IMODALS study paves the way for MIROCALS

Reading Time: 4 minutes Although ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in the immune system might play a role in influencing the course of the disease. This is a subject we’ve covered before, with particular reference to the ongoing MIROCALS drug trial…

Clinical Trials (Part 1) – Platform Presentations: Highlights from Perth

Clinical Trials (Part 1) – Platform Presentations: Highlights from Perth

Reading Time: 4 minutes This blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and posters presented at the 30th International Symposium on ALS/MND. All presentations have a code beginning with ‘C’ followed by a number (e.g. C50). This will help you locate the specific…

TUDCA-ALS has started recruiting in the UK

TUDCA-ALS has started recruiting in the UK

Reading Time: 3 minutes TUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure 1). The Consortium aims to find a new treatment to slow down the progression of MND/ALS by conducting a clinical trial to investigate the safety and efficacy (effectiveness) of Tauroursodeoxycholic…

ALSUntangled – untangling the mysteries of alternative and off-label treatments

ALSUntangled – untangling the mysteries of alternative and off-label treatments

Reading Time: 5 minutes There are literally thousands of websites on the internet that make claims about amazing alternative or off-label treatments (AOTs) and even cures for MND but with little or no scientific evidence to back these claims up. This presents a real problem for people living with the disease who may want to try them. Are they…

New gene therapy targeting C9orf72-ALS begins Phase 1 clinical trial in the UK

New gene therapy targeting C9orf72-ALS begins Phase 1 clinical trial in the UK

Reading Time: 2 minutes This article was written by Dr Keith Mayl and Dr Ahmad Al Khleifat of King’s College London. Researchers at King’s College Hospital, led by Professor Christopher Shaw, have embarked on the first gene therapy clinical trial for patients affected by a specific genetic form of ALS, the most common type of MND. ALS is a…

How animals are helping to improve our understanding of MND

How animals are helping to improve our understanding of MND

Reading Time: 6 minutes ‘From antibiotics and insulin to blood transfusions and treatments for cancer or HIV, virtually every medical achievement in the past century has depended directly or indirectly on research using animals’ – from the Royal Society’s position statement on the use of animals in research. We know that talking about using animals in research is an…